title: Pediatric lupus nephritis: Management update.
abstract: Childhood-onset systemic lupus erythematosus (cSLE) is a severe multisystem autoimmune disease. Renal involvement occurs in the majority of cSLE patients and is often fatal. Renal biopsy is an important investigation in the management of lupus nephritis. Treatment of renal lupus consists of an induction phase and maintenance phase. Treatment of childhood lupus nephritis using steroids is associated with poor outcome and excess side-effects. The addition of cyclophosphamide to the treatment schedule has improved disease control. In view of treatment failure using these drugs and a tendency for non-adherence, many newer agents such as immune-modulators and monoclonal antibodies are being tried in patients with cSLE. Trials of these novel agents in the pediatric population are still lacking making a consensus in the management protocol of pediatric lupus nephritis difficult.
authors.affiliation: Rajiv Sinha, Division of Pediatric Nephrology, Department of Pediatrics, Institute of Child Health, Kolkata 700017, India.
authors.forename: Rajiv
authors.initials: R
authors.lastname: Sinha
authors.affiliation: Rajiv Sinha, Division of Pediatric Nephrology, Department of Pediatrics, Institute of Child Health, Kolkata 700017, India.
authors.forename: Sumantra
authors.initials: S
authors.lastname: Raut
keywords: Cyclophosphamide; Lupus nephritis; Management; Monoclonal antibody; Mycophenolate mofetil; Pediatric